© 2021 - Negotiamini. All Rights Reserved.
The hepatitis C virus (HCV) is a global health concern, because of its progression to cirrhosis, hepatocellular cancer, and liver transplantation, among others.
On a worldwide scale, it is reported that about 17 million people live with HCV, with as many as 399,000 deaths attributed to HCV-related liver disease in 2017. 3 The increasing health care impact of HCV has been viewed as a cause for concern for many years.
About 2.4 million Americans were living with HCV between 2013 and 2016, according to the CDC.
With the highly publicized development of new HCV medications, such as direct-acting antivirals, polymerase inhibitors, and protease inhibitors, as well as improved screening, many were hopeful that HCV could be almost eradicated in the United States.
However, millions of Americans have yet to benefit from these curative therapeutic agents.
For instance, even though the advent of direct-acting antivirals have demonstrated a significant paradigm shift in the treatment approach of chronic HCV infection, with more favorable adverse effect profiles than older agents and observed cure rates of greater than 90%, there are still patients who do not have access to these life-changing drugs.
Given these noteworthy findings, the United States continues to […]